RAS and ROS in rhabdomyosarcoma
- PMID: 24332036
- PMCID: PMC3985483
- DOI: 10.1016/j.ccr.2013.11.015
RAS and ROS in rhabdomyosarcoma
Abstract
The 5-year survival for localized rhabdomyosarcoma is over 70%, but only 30% for patients presenting with metastatic disease. In this issue of Cancer Cell, Chen and colleagues performed whole-genome and RNA sequencing on human rhabdomyosarcoma and identified RAS mutations and oxidative stress as potential therapeutic targets for high-risk embryonal rhabdomyosarcoma.
Copyright © 2013 Elsevier Inc. All rights reserved.
Comment on
-
Targeting oxidative stress in embryonal rhabdomyosarcoma.Cancer Cell. 2013 Dec 9;24(6):710-24. doi: 10.1016/j.ccr.2013.11.002. Cancer Cell. 2013. PMID: 24332040 Free PMC article.
References
-
- Chen, et al. 2013 this issue.
-
- Ferrari A, Bisogno G, Macaluso A, Casanova M, D’Angelo P, Pierani P, Zanetti I, Alaggio R, Cecchetto G, Carli M. Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer. 2007;109:1406–1412. - PubMed
-
- Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine. 1987;66:98–113. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
